Pulmonary Arterial Hypertension Market – Industry Analysis and Forecast (2022-2029)


Pulmonary Arterial Hypertension Market size was valued at US$ 5.97 Bn in 2021 and the total revenue is expected to grow at 4.9 % through 2022 to 2029, reaching nearly US$ 8.76 Bn.

Pulmonary Arterial Hypertension Market Overview:

Pulmonary arterial hypertension is a life-threatening condition that develops with time, but therapies can alleviate symptoms and help a person live for a longer period of time with the disease more comfortably. It may require some forethought, but many individuals with it find ways to do everything they like, just as they did before they were diagnosed. A person suffering from pulmonary arterial hypertension has high blood pressure in arteries that pass from the heart to the lungs.Pulmonary Arterial Hypertension MarketTo know about the Research Methodology :- Request Free Sample Report

Pulmonary Arterial Hypertension Market Dynamics:

With the rising prevalence of PAH (pulmonary arterial hypertension), the expanding elderly population, and increased government funding for the development of orphan medicines, the market is anticipated to rise significantly over the forecast period. However, due to a variety of reasons, including an unhealthy lifestyle, lack of movement, rising HIV patients, excess consumption of smoking and alcohol/tobacco, and other idiopathic diseases, the prevalence of the factor of PAH has increased in recent years. Patients experiencing pulmonary arterial hypertension are more prone to developing COVID-19. As of August 2021, the incidence rate of COVID-19 infection in PAH patients was 2.1 cases per 1,000 patients, according to the American College of Cardiology. As a consequence, there was a spike in demand for PAH medications to treat COVID-19 infection. The market's expansion was supported through this demand.

In Additions, major market players are investing a huge amount in new product launches and innovations to offer precise treatment options. For illustration, United Therapeutics licensed a Remunity pump for Remodulin to treat pulmonary arterial hypertension in February 2021. In comparison to current subcutaneous pump alternatives, this device is tiny, compact, and preloaded with medicine, leading to better results. Over the projected period, this is expected to have a significant impact on total market growth. Further, mergers and collaborations play an important role in market expansion.

Pulmonary Arterial Hypertension Market Segment Analysis:

The prostacyclin and prostacyclin analogs segment are anticipated to adhere to the growth of the Pulmonary Arterial Hypertension Market.

The prostacyclin and prostacyclin analogs are estimated to dominate the growth of the pulmonary arterial hypertension market with the largest market share of 45% in 2021. The growth is attributed to the high demand for drugs and the proliferation of life-threatening diseases. The prostacyclin and analogs market is likely to develop noticeably in the forecast period, owing to the increased consumption of oral prostacyclin sub-segment such as Uptravi and Orenitram. Moreover, Prostacyclin, popularly known as prostaglandin I-2 (PGI-2), is a tiny lipid eicosanoid molecule generated by endothelial cells that works locally to suppress platelet activity and cause vasodilation. Prostacyclin analogs have been explored as treatments for pulmonary arterial hypertension (PAH).

From 2022 to 2029, the SGC (Soluble Guanylate Cyclase) simulators segment is anticipated to grow at the quickest rate of 12.3%. By potentiating NO-SGC signaling, SGC (Soluble Guanylate Cyclase) stimulators can assure maximal SGC activation. The single medication authorized for PAH (Pulmonary Arterial Hypertension) in this category is Riociguat (Adempas from Bayer company). Also, ERA and PDE-5 sectors are predicted to grow significantly and lift the market expansion in the coming years.

Pulmonary Arterial Hypertension Market Regional Segment:

North America dominated the PAH (Pulmonary Arterial Hypertension) market with a share of 57.74% in 2021 due to the sophisticated healthcare infrastructure in the United States, which enabled access to innovative medicines and healthcare treatment. In addition, the expansion of the regional market was guided by increasing awareness, a high diagnosis rate, and supporting government efforts. In addition, a good diagnostic rate was achieved owing to a well-planned compensation system and strong awareness. Furthermore, in the United States, supporting laws such as the Rare Disease Act of 2002 and the Orphan Drug Act (ODA) of 1983 aided the development of new PAH medications. Hence, these factors are estimated to motivate the regional market. Further, the dominating countries of North America are the US, Canada, and Mexico.

Europe is estimated to gain significant market growth in the forecast timeframe. Moreover, the presence of government agencies such as the European Medicines Agency (EMA) and the European Society of Cardiology promoting early and preventive diagnosis of PAH (Pulmonary arterial hypertension) is likely to motivate the growth of the market in the future. The factors boosting the European market are the rising occurrence of chronic diseases such as HIV, PAH, cardiovascular diseases, and various others. Further, increasing elderly populations, changes in lifestyle patterns, immobility in daily routine, and pollutions in the environment are likely to boost the market growth.

The objective of the report is to present a comprehensive analysis of the Pulmonary Arterial Hypertension Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Pulmonary Arterial Hypertension Market dynamics, structure by analyzing the market segments and project the Pulmonary Arterial Hypertension Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Pulmonary Arterial Hypertension Market make the report investor’s guide.

Pulmonary Arterial Hypertension Market Scope: Inquire before buying






Global Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 5.97 Bn.




Forecast Period 2022 to 2029 CAGR:
4.9%
Market Size in 2029:
US $ 8.76 Bn.




 Segments Covered:
by Drug Class
• Prostacyclin and Prostacyclin Analogs
• Soluble Guanylate Cyclase (SGC) Stimulators
• Endothelin Receptor Antagonist (ERA)
• Phosphodiesterase 5 (PDE-5)






Pulmonary Arterial Hypertension Market, by Region

• North America
o US
o Canada
o Mexico
• Europe
o U.K
o France
o Germany
o Italy
o Spain
o Sweden
o CIS Countries
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o ASEAN
o Rest of Asia Pacific
• Middle East and Africa
o South Africa
o GCC Countries
o Egypt
o Nigeria
o Rest of ME&A
• South America
o Brazil
o Argentina
o Rest of South America

Pulmonary Arterial Hypertension Market Key Players

• Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.
• United Therapeutics Corporation
• GlaxoSmithKline Plc. (GSK);
• Roivant Sciences
• Accredo.
• Liquidia Corporation
• Pfizer, Inc.
• Acceleron Pharma, Inc.
• Bayer AG
• Janssen Türkiye
• Trident Life Sciences Ltd
• PhaseBio Pharmaceuticals, Inc.
• Domedica
• Biozeus Biopharmaceuticals

FAQs:

1. What is the Pulmonary Arterial Hypertension Market share in 2021?
Ans: The Pulmonary Arterial Hypertension Market share in 2021 was estimated as 5.97 Billion USD.

2. What is the Pulmonary Arterial Hypertension Market growth?
Ans: The Pulmonary Arterial Hypertension Market is anticipated to grow with a CAGR of 4.9% in the forecast period and is likely to reach USD 8.76 Billion by the end of 2029.

3. Which Drug Class segment is expected to dominate the Pulmonary Arterial Hypertension Market during the forecast period?
Ans: The prostacyclin and prostacyclin analogs segment captured the largest share of over 45.0% in 2021 owing to the high demand for these drugs. Further oral prostacyclin subsegments such as uptravi and orenitram are likely to create more opportunities in the market.

4. Which region is expected to dominate the Pulmonary Arterial Hypertension Market during the forecast period?
Ans: North America dominated the PAH market with a share of 57.74% in 2021. This is attributable to the developed healthcare infrastructure in the U.S. that facilitates access to advanced therapeutics for treating pulmonary arterial hypertension. A well-planned reimbursement structure and high awareness resulted in an excellent diagnosis rate of PAH.

5. What is the key driving factor for the growth of the Pulmonary Arterial Hypertension Market?
Ans: Supportive legislation such as the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. has increased the adoption of novel medication for treating PAH. Hence this key factor is projected to drive the growth of the market. 




1. Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Technology
2.3.2. Primary Research
2.3.2.1. Data from Primary Technology
2.3.2.2. Breakdown of Primary Technology
3. Executive Summary: Pulmonary Arterial Hypertension Market Size, by Market Value (US$ Bn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2021
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Pulmonary Arterial Hypertension Market
3.4. Geographical Snapshot of the Pulmonary Arterial Hypertension Market, By Manufacturer share
4. Pulmonary Arterial Hypertension Market Overview, 2021-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porter Five Forces Analysis
4.1.6.1. Threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. Threat of Substitute Grades
4.1.6.5. Intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Pulmonary Arterial Hypertension Market
5. Supply Side and Demand Side Indicators
6. Pulmonary Arterial Hypertension Market Analysis and Forecast, 2021-2029
6.1. Pulmonary Arterial Hypertension Market Size & Y-o-Y Growth Analysis.
7. Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
7.1. Market Size (Value) Estimates & Forecast By Drug Class, 2021-2029
7.1.1. Prostacyclin and Prostacyclin Analogs
7.1.2. Soluble Guanylate Cyclase (SGC) Stimulators
7.1.3. Endothelin Receptor Antagonist (ERA)
7.1.4. Phosphodiesterase 5 (PDE-5)
8. Pulmonary Arterial Hypertension Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
9.1. Market Size (Value) Estimates & Forecast By Drug Class, 2021-2029
9.1.1. Prostacyclin and Prostacyclin Analogs
9.1.2. Soluble Guanylate Cyclase (SGC) Stimulators
9.1.3. Endothelin Receptor Antagonist (ERA)
9.1.4. Phosphodiesterase 5 (PDE-5)
10. North America Pulmonary Arterial Hypertension Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
11.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
12. Canada Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
12.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
13. Mexico Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
13.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
14. Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
14.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
15. Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
16.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
17. France Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
17.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
18. Germany Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
18.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
19. Italy Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
19.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
20. Spain Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
20.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
21. Sweden Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
21.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
22. CIS Countries Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
22.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
23. Rest of Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
23.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
24. Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
24.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
25. Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
26.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
27. India Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
27.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
28. Japan Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
28.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
29. South Korea Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
29.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
30. Australia Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
30.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
31. ASEAN Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
31.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
32. Rest of Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
32.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
33. Middle East Africa Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
33.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
34. Middle East Africa Pulmonary Arterial Hypertension Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
35.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
36. GCC Countries Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
36.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
37. Egypt Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
37.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
38. Nigeria Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
38.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
39. Rest of ME&A Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
39.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
40. South America Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
40.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
41. South America Pulmonary Arterial Hypertension Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
42.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
43. Argentina Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
43.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
44. Rest of South America Pulmonary Arterial Hypertension Market Analysis and Forecasts, 2021-2029
44.1. Market Size (Value) Estimates & Forecast By Drug Class’s, 2021-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Pulmonary Arterial Hypertension Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment
45.2.2. New Grade Launches and Grade Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment, and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements
45.3. Company Profile: Key Players
45.3.1. Biozeus Biopharmaceuticals.
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Grade Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Developments
45.3.2. Johnson & Johnson Services, Inc.
45.3.3. Gilead Sciences, Inc.
45.3.4. United Therapeutics Corporation
45.3.5. GlaxoSmithKline Plc. (GSK);
45.3.6. Roivant Sciences
45.3.7. Accredo.
45.3.8. Liquidia Corporation
45.3.9. Pfizer, Inc.
45.3.10. Acceleron Pharma, Inc.
45.3.11. Bayer AG
45.3.12. Janssen Türkiye
45.3.13. Trident Life Sciences Ltd
45.3.14. PhaseBio Pharmaceuticals, Inc.
45.3.15. Domedica
45.3.16. Biozeus Biopharmaceuticals
46.Primary Key Insights

About This Report

Report ID 122335
Category Healthcare
Published Date Oct 2022
Updated Date